• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Foundation Medicine Acquires Precision Oncology Company Lexent Bio

by Fred Pennic 06/12/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Foundation Medicine Acquires Precision Oncology Company Lexent Bio

What You Should Know:

– Foundation Medicine acquires Lexent Bio, a precision oncology company developing novel liquid biopsy platforms.

– The acquisition will accelerate Foundation Medicine’s liquid biopsy R&D and advance cancer care through an expansion of multiomics capabilities. 


Foundation Medicine, Inc., announced that it has completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. Foundation Medicine is a molecular insights company that offers a portfolio of comprehensive genomic profiling services to connect patients to cancer treatments and advanced precision medicine. This acquisition will accelerate Foundation Medicine’s research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients.

Acquisition Expands Foundation Medicine’s Liquid Biopsy R&D Efforts

Specifically, the acquisition enables Foundation Medicine to:

– Expand its core R&D capabilities to include a new emphasis on multiomics, including the incorporation of DNA methylation into biomarkers for cancer progression across all stages of disease, including early stage

– Expand its portfolio offerings to evaluate cancer progression in broader patient populations

– Enhance its ability to capture longitudinal data with serial patient sampling; and

– Accelerate its early R&D pipeline and support new approaches for developing targeted therapies, from discovery research through clinical development.


Lexent Bio’s novel monitoring platform is currently in development and is based on low-pass whole-genome sequencing (WGS) and DNA methylation analysis. Foundation Medicine plans to further incorporate WGS and methylation into new assay platforms to support treatment decision-making across all stages of the disease. Methylation analysis has been shown to reveal important aspects of underlying cancer biology and allows oncologists to identify patients at high risk of disease progression, potentially intervene sooner and improve patient outcomes in earlier stages of disease.

These collective capabilities will enable the expansion of Foundation Medicine’s current tumor-informed personalized cancer monitoring initiatives into universal tumor-agnostic approaches in the future.

This technology adds to Foundation Medicine’s portfolio of tissue and liquid biopsy platforms and will aim to support new approaches for developing targeted therapies, from discovery research through clinical development. With this acquisition and the integration of Lexent Bio’s monitoring platform, Foundation Medicine will expand its capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early and late-stage disease, ultimately bringing new options to oncologists and patients.

“Lexent Bio’s platforms align well with our liquid biopsy research and development strategy, which ultimately aims to bring the latest research innovations into routine clinical use in metastatic disease and at potentially earlier stages of patient care,” said Cindy Perettie, chief executive officer at Foundation Medicine. “They bring with them an accomplished group of clinicians, scientists and engineers who share our patient-centric, science-first mission to transform cancer care. We’re thrilled to welcome them to our team and look forward to their contributions to our research and development efforts to deliver new breakthroughs that advance precision medicine and patient care.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Healthcare Mergers & Acquisitions

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |